ACE1831 is a new treatment being studied for people with IgG4-Related Disease (IgG4-RD), a condition where the immune system mistakenly attacks the body. The study is looking at how safe and effective this treatment is. Participants will receive cells called gamma delta T (gdT) cells, which come from healthy donors and may help treat the disease.
Key Points:
- The study is open-label, meaning everyone knows they are receiving ACE1831.
- Participants must be between 18-75 years old and have active IgG4-RD affecting at least two body parts.
- Participants will need to follow specific guidelines, like not getting pregnant and stopping certain medications.
Not everyone can join. People with serious infections, severe heart problems, or recent cancer may not be eligible. The study wants to ensure that the treatment is both safe and helpful. Participants will need to visit the study center for check-ups and may need to take other medicines, like glucocorticoids, during the study.
How understandable was the trial content above?
Hard to understand
Easy to understand